Heparin for infants and children with meningococcal septicemia. Results of a randomized therapeutic trial.
Heparin has been given intravenously, as part of a prospective study, to 11 of 26 infants and children with severe meningococcal septicemia. This therapy was started as early as possible following admission to hospital, and continued for two days. The age and sex distributions were roughly similar for the two treatment groups, but the prognostic signs on admission were somewhat less favourable for the group that did not receive heparin. Two boys who received heparin and two girls who did not, died. The clinical courses of the surviving patients in the two groups were also roughly similar, except that the tendency to cutaneous necroses was slightly more prominent in those who had not received heparin. We have thus no evidence that heparin has any great influence on the final outcome of meningococcal septicemia, even when given so early that shock had not developed.
D002648:Child; D002986:Clinical Trials as Topic; D005260:Female; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D008297:Male; D008589:Meningococcal Infections / Q000188:drug therapy*; D011897:Random Allocation; D018805:Sepsis / Q000188:drug therapy*
D006493:Heparin